Cargando…
Cardiovascular Risk Profile of Chimeric Antigen Receptor T-cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy is a novel form of immunotherapy that has been recently introduced in clinical practice for the treatment of leukemias and lymphomas after being approved by United States Food and Drug Administration (USFDA). The risk profile of this treatment modality...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186087/ https://www.ncbi.nlm.nih.gov/pubmed/32351816 http://dx.doi.org/10.7759/cureus.7436 |